Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

ClinicalTrials.gov ID: NCT00108953

Public ClinicalTrials.gov record NCT00108953. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).

Study identification

NCT ID
NCT00108953
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bayer
Industry
Enrollment
96 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2005 (Type not available)
Primary completion
Apr 2008 (Actual)
Completion
Apr 2008 (Actual)
Last update posted
Oct 31, 2014

2005 – 2008

United States locations

U.S. sites
15
U.S. states
9
U.S. cities
14
Facility City State ZIP Site status
Not listed Birmingham Alabama 35294 —
Not listed Beverly Hills California 90211-1850 —
Not listed Orange California 92668-3298 —
Not listed Palo Alto California 94304-1207 —
Not listed San Francisco California 94115 —
Not listed San Francisco California 94121 —
Not listed Sylmar California 91342 —
Not listed Miami Florida 33136 —
Not listed Lafayette Louisiana 70506 —
Not listed Minneapolis Minnesota 55455 —
Not listed Hackensack New Jersey 07601 —
Not listed New York New York 10065 —
Not listed Rochester New York 14642 —
Not listed Nashville Tennessee 37203 —
Not listed Seattle Washington 98101 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00108953, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 31, 2014 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00108953 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →